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blood samples from her relatives. The prevalence of the
mutations in the TIGR gene was 4.0% (2/50 families),
which was comparable to that reported in a previous
study (Stone et al. 1997).
The present study has revealed that mutations in the
TIGR gene are also responsible for familial POAG in
Japan. The mutations in the third exon of the TIGR
gene were found to be associated with ∼4% of Japanese
familial POAG patients. The prevalence of themutations
in the gene was comparable in Japanese patients and in
the population previously studied. The mutated sites,
however, were different from those reported in the pre-
vious study, and no common mutations were found.
Therefore, the distribution of the mutated sites in the
TIGR gene in Japanese POAG may be different from
those in other races. Known mutated sites in the TIGR-
gene disease alleles are at the 364th, 367th, 368th,
370th, and 437th amino acid residues. The apparent
focus of the reported mutations—around the 367th
amino acid residue—indicates that the amino acid
change around this position may play a critical role in
the pathogenesis of POAG. The TIGR-protein product
is overexpressed with glucocorticoid stimulation and is
thought to contribute to steroid-responsive intraocular-
pressure increase, by the obstruction of aqueous outflow
(Nguyen et al. 1993; Polansky et al. 1997). Further in-
vestigations of the TIGR gene will reveal more infor-
mation about the pathogenesis of POAG.
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Childhood Cancer and Neural Tube Defects
To the Editor:
In the March 1997 issue of the Journal, Narod et al.
(1997) concluded that cases of spina bifida and of ab-
normalities of the eye, ribs, and spine were more com-
mon in children with cancer than among population-
based controls. In an invited editorial in the same issue,
Friedman (1997) called for additional work to define
more clearly the associations between congenital anom-
alies and cancer and to differentiate those associations
that are spurious from those that are biologically
important.
I wish to comment on the reported association be-
tween spina bifida and cancer, which was based on com-
parison of the relative frequency of specific types of
anomalies in children with cancer who were diagnosed
in Great Britain during the period 1971–86 with the
corresponding relative frequency in liveborn children
born in British Columbia during the period 1969–88. In
addition to the differences in methods of ascertainment
discussed by Narod et al. (1997), this comparison ap-
pears to be inappropriate, since the prevalence of neural
tube defects at birth was markedly higher in the British
Isles than in Canada, from the 1950s to the early 1980s
(Little and Elwood 1992). This difference was apparent
despite the decline in the prevalence of these defects at
birth in the British Isles since the early 1970s. In Canada,
there has been a persistent east-west gradient, with the
prevalence at birth declining from the east toward the
west.
In the study by Narod et al. (1997), when the 275
cases with an established genetic cause were excluded,
the prevalence of neural tube defects at birth among
children diagnosed with childhood cancer was 1.2 per
1,000 births. As noted by Narod et al., anencephalus is
associated with a high rate of infant mortality, and most
children with neural tube defects are likely to have had
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spina bifida. In studies of births in Great Britain prior
to 1979, the prevalence of spina bifida at birth was
within the range of 1.5–4.1 per 1,000 births, and, in
studies in the early 1980s, the prevalence was within the
range of 0.7–1.9 per 1,000 births (Little and Elwood
1992). Some of these infants would have been stillborn.
For example, in Northern Ireland during the period
1974–79, 15.5% of 569 cases of spina bifida or encepha-
lacoele were stillborn (Little and Nevin 1989). In Glas-
gow and Liverpool during the period 1980–92, when
fetuses from terminated pregnancies were excluded,
16% of 262 cases of spina bifida were recorded to have
resulted in fetal deaths (EUROCAT Working Group
1995). Therefore, it appears that the proportion of cases
of childhood cancer with neural tube defects is similar
to what would be expected on the basis of data on the
prevalence of these defects at birth, in Great Britain.
In the study by Narod et al. (1997), eight of the chil-
dren with tumors of the brain or of the spinal cord were
recorded as having spina bifida, compared with the 5.6
expected on the basis of the frequency of spina bifida
among children with other types of cancer in Great Brit-
ain and with the 2.4 expected on the basis of the data
for British Columbia. Again, the proportion of children
with tumors of the brain or of the spinal cord who were
recorded as having spina bifida (1.7 per 1,000 births)
would appear to be within the range of prevalences at
birth reported for Great Britain during the period in
which the children included in the study by Narod et al.
would have been born. Thus, the study by Narod et al.
does not appear to support the hypothesis of a common
maternal factor for brain tumors and spina bifida.
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Reply to Little
To the Editor:
My colleagues and I thank Dr. Little (1997 [in this issue])
for his important data. We saw an excess of neural tube
defects in children with cancer, in the United Kingdom,
compared with healthy controls from British Columbia.
It is unclear to what extent the control group from Brit-
ish Columbia was comparable to the children from Brit-
ain, and our approach is inadequate when the baseline
rates of disease differ for the two countries. Unlike the
rates of other malformations, the rate of spina bifida
was not significantly greater in children with solid tu-
mors than in those with leukemia. We agree that our
data do not allow us to conclude that there is an excess
of cancer among children with neural tube defects.
STEVEN NAROD
The Centre for Research in Women’s Health
Toronto
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Lafora Progressive Myoclonus Epilepsy: Narrowing
the Chromosome 6q24 Locus by Recombinations
and Homozygosities
To the Editor:
Lafora disease (LD) is an autosomal recessive and rare
but fatal epilepsy syndrome characterized by stimuli-sen-
sitive myoclonus, absence and grand mal seizures, pro-
gressive intellectual and neurological deterioration, and
periodic acid Schiff (PAS) stain–positive intracellular in-
clusion bodies. Eighty-four years after Gonzalo Lafora
